Seasoned corporate investors know they can't absorb every founder claim and C-suite opinion. Here's what can and should be tuned out.
Experience is an excellent teacher—especially in corporate venture capital, where the classroom consists of rotating pitch meetings, internal strategy reviews, “quick syncs,” and the recurring existential question: Wait, why do we exist again?
Over time—through repetition, scars, and an unreasonable amount of caffeine—CVC practitioners develop a skill that matters far more than pattern recognition or deal flow:
Selective hearing.
Newcomers tend to believe success in CVC comes from absorbing everything: every founder claim, every market narrative, every internal opinion delivered with confidence.
This is understandable. It’s also unsustainable.
In practice, effectiveness depends on knowing what not to hear, what not to react to, and what not to take at face value. Experience teaches you to ignore—politely, strategically, and without apology.
Here are some of the things seasoned CVC investors learn to tune out, from both the startup and the parent corporation.
What to tune out from startups:
Ignore the founder who claims every customer is “desperate” – without naming one
Early in your career, you lean forward when a founder says: “Customers are begging us for this.” With experience, you learn that “begging” often means “mentioned once at a conference happy hour.”
An internal translation begins to run automatically:
- “Customers are desperate” → We talked to someone who was encouraging
- “The industry is ready” → We hope someone else validates this first
- “Strong LOI interest” → We sent an email and didn’t receive a no
You nod, thank them, and move on—saving your energy for battles that matter, like negotiating procurement’s 29-page onboarding process.
Ignore pitch decks with more than three gradients
This is not aesthetic judgment; it’s pattern recognition.
- One gradient: fine
- Two gradients: ambitious
- Three gradients: someone discovered Canva last night
- Four or more: more time went into slide design than into building a data room
At that point, you can safely discount a meaningful portion of what follows.
Ignore the hockey stick that starts today
Every pitch includes a revenue curve that appears to be experiencing a medical event—flat, flat, flat, then vertical. New analysts stare in awe. Experienced investors don’t bother reacting.
You already know:
- The assumptions are fragile
- The timing is imaginary
- The curve is a requirement, not a forecast
Experience, however, teaches you to ignore the graph entirely. You know the truth: hockey-stick revenue curves are as fundamental to startup pitch decks as oxygen is to human life. Ignoring them saves you time and prevents recurring heartburn.
Hear Bill Taranto speak at the GCV Symposium in London on June 23rd, 2026.
Taranto will be moderating a panel discussion on the intersection of corporate investment and public capital in Europe’s investment landscape.
Ignore valuations that would make a sovereign wealth fund pause
When CVC investors are new to the game, newcomers panic when a pre-revenue startup proposes a nine-figure valuation.
“Is that… allowed?” they ask.
Experience brings calm. These numbers aren’t real; they’re aspirational. You read them the way you read science fiction—with interest, skepticism, and emotional distance.
When the founder eventually asks about valuation, you respond with the professional equivalent of: Let’s all pretend we didn’t see that slide.
Ignore any slide titled “Synergies”
The synergy slide is a corporate staple: arrows pointing at abstract nouns—Alignment. Acceleration. Value Creation.
In theory, it explains how two organizations will work together. In practice, it means: We’ll figure this out later.
Experienced investors know that real synergies emerge after a deal closes—or not at all. PowerPoint arrows have never generated revenue.
Ignore anyone who needs an investment “by Friday”
Urgency of this sort is a reliable warning sign.
Veterans know:
- Friday is an artificial deadline
- “Other investors” are often imaginary
- The data room will contain three files, one of which is a headshot
You reply calmly: “We’ll take a closer look next week.” The deadline almost always disappears.
From the corporation:
Ignore the phrase: “We just need a small pilot to prove value”
In corporate venture, “small pilot” usually translates into:
- Months of emails
- Security reviews requesting documents you don’t have
- Procurement forms that multiply overnight
- A sponsor who changes roles halfway through
- A project costing $8,200 and 240 hours of your life
Experience teaches you to hear “small pilot” the way a parent hears “I’ll clean my room later.”
Ignore the eternal debate: Strategic vs financial returns
This debate resurfaces annually. Slides are prepared. Consultants are engaged. The same frameworks reappear, unchanged, year after year.
Experience teaches you the only rule that matters is you need both:
- When times are good, emphasize strategic value
- When times are tough, explain why returns don’t beat the S&P 500
Everything else is philosophical theater.
Ignore corporate executives who suddenly care deeply about your portfolio strategy
Once a quarter, an executive with no prior interest in venture capital will “drop in” to offer strategic guidance. It will be:
- Unrelated to your actual mandate
- Based on something overheard in an airport lounge
- Delivered with unwavering confidence
Experience teaches you to listen attentively—and then do nothing. In a few weeks, they won’t remember attending the meeting. Shortly after that, they’ll advocate the opposite position with equal conviction.
Ignore the internal colleague who says: “We should just build this ourselves”
This suggestion typically comes from someone without budget, team, or technical capacity—but with extraordinary confidence.
Experience teaches you not to engage. In many corporations, “building it themselves” remains largely a theoretical discussion rather than an operational capability.
Selective hearing isn’t how you avoid the work—it’s how you find it. In a system designed to amplify ambition, urgency, and optimism, the discipline to ignore most of what you hear is what creates space for the few conversations that lead to partnerships, progress, and outcomes.
I’d love to hear your thoughts. If my opinion resonates with you or raises questions, let’s continue the conversation. Feel free to share your comments, feedback, or experiences with me on LinkedIn where I will also be posting on CVC Compass.
Bill Taranto is president of MSD Global Health Innovation Fund and vice president of MSD Global Health Innovation Group. MSD GHIF has $600M under management and provides growth capital to companies that improve healthcare delivery and services.
For more than a decade, GHIF has invested in artificial intelligence and now backs 15 AI-enabled companies across drug discovery, clinical trials, supply chain, and patient access, using AI as a core capability to accelerate how the industry discovers, develops, and delivers new medicines.
